Spruce Biosciences (NASDAQ:SPRB) Price Target Cut to $150.00 by Analysts at HC Wainwright
HC Wainwright cut its price target for Spruce Biosciences (NASDAQ:SPRB) from $200 to $150 and kept a “buy” rating, according to a Monday research note cited by Benzinga. The target implies 192.57% upside versus the prior close. Other analysts cited include Oppenheimer “outperform” and Citizens JMP reducing its target to $150. Spruce reported ($8.94) EPS for the quarter on May 13, missing consensus ($7.93).
How this was made
The 30-second read
Why it matters
The main incremental datapoint is the HC Wainwright target reduction to $150, alongside other analyst target changes (Citizens JMP also cut to $150). This can influence short-term sentiment and expectations for valuation, but the article does not introduce new clinical results or guidance.
Market read
A sell-side target reset for SPRB can move sentiment for a high-beta small-cap biotech, especially after a recent earnings miss, but it is not a new fundamental catalyst in the article.
What to watch
The article cites a recent earnings miss (May 13) and high beta; price action may be driven more by upcoming trial/financing expectations than by incremental target changes.
Background
Spruce Biosciences is a clinical-stage biopharma focused on rare endocrine/dermatological disorders; its lead asset is tildacerfont for congenital adrenal hyperplasia.
Ticker impact
HC Wainwright cut its SPRB price target from $200 to $150 while maintaining a Buy rating, signaling revised valuation expectations.
Mild downside bias possible on analyst-target headlines; magnitude likely limited unless other firms follow with downgrades.
The article is a research-target change (not a new clinical/regulatory datapoint). It includes both target cuts and continued Buy/Outperform ratings, suggesting sentiment impact but not a fundamental reset.
Market effects
For clinical-stage biopharma, repeated target trims can reflect higher risk discounting even without new trial outcomes.
None specific beyond US small-cap biotech sentiment.
Limited; this is company-specific sell-side valuation commentary.
Counterpoint
Target cuts can be backward-looking valuation adjustments; if upcoming clinical milestones de-risk tildacerfont, the market may re-rate despite lower targets.
Key entities
- companySpruce Biosciences
Subject of the analyst price-target cut; NASDAQ-listed biotech developing tildacerfont.
- analyst_firmHC Wainwright
Cut SPRB price target from $200 to $150 and kept a Buy rating.
- analyst_firmCitizens JMP
Cut its SPRB price target from $170 to $150 and set Market Outperform.
